Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration-Approved Anticancer Drugs: A Call for Systematic Data Availability.

Modi, Natansh D; Swain, Sandra M; Buyse, Marc; Kuderer, Nicole M; Rowland, Andrew; Rockhold, Frank W; Sorich, Michael J; Hopkins, Ashley M · J Clin Oncol · 2024

review · Level V

Where this comes from

Abstract

Unlocking the full potential of clinical trials through comprehensive CSR and IPD sharing can revolutionize cancer care, enhance safety evaluations, and reduce bias in systematic reviews. It is time for all stakeholders to embrace transparency and advance patient-centered outcomes.

Medical subject headings